Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Feedback ( (GB:FDBK) ) has shared an announcement.
Feedback plc has disclosed that chief executive Tom Oakley and non-board chief financial officer Emma Oswick have both increased their holdings in the company through on-market share purchases on 23 December 2025. Oakley bought 60,904 ordinary shares at 8.19 pence each, taking his total beneficial interest to 110,904 shares, or 0.25% of the company’s issued share capital, while Oswick acquired 60,459 shares at 8.27 pence each, establishing a 0.14% stake. The director and PDMR dealings, conducted on AIM in London, signal closer alignment of senior management with shareholders at a time when Feedback is pursuing growth opportunities for its healthcare data and collaboration platforms in domestic and international markets.
Spark’s Take on GB:FDBK Stock
According to Spark, TipRanks’ AI Analyst, GB:FDBK is a Neutral.
Feedback plc’s overall score reflects a mixture of strengths and challenges. Strong balance sheet and strategic corporate alignments are positive, but persistent losses and cash flow issues raise concerns. Technical analysis indicates a bearish trend, while valuation metrics highlight difficulties due to negative earnings.
To see Spark’s full report on GB:FDBK stock, click here.
More about Feedback
Feedback plc is a UK-based clinical infrastructure specialist that develops software-as-a-service platforms to connect disparate healthcare IT systems and streamline patient pathways. Its core products include Bleepa, a regulated communication and collaboration tool that displays clinical results to support multidisciplinary team working, and CareLocker, a patient-facing platform that provides individuals with access to and control over their diagnostic and clinical data. The company targets both public and private healthcare markets, including the NHS, aiming to improve clinical workflows, care coordination and patient outcomes while building scalable, recurring revenues.
Average Trading Volume: 85,391
Technical Sentiment Signal: Strong Sell
Current Market Cap: £3.44M
Learn more about FDBK stock on TipRanks’ Stock Analysis page.